CN110621298B - 阿托品药物组合物 - Google Patents

阿托品药物组合物 Download PDF

Info

Publication number
CN110621298B
CN110621298B CN201880031247.6A CN201880031247A CN110621298B CN 110621298 B CN110621298 B CN 110621298B CN 201880031247 A CN201880031247 A CN 201880031247A CN 110621298 B CN110621298 B CN 110621298B
Authority
CN
China
Prior art keywords
atropine
composition
ophthalmic
weight
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880031247.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110621298A (zh
Inventor
纳瓦尼特·普里
普雷姆·萨格尔·阿卡萨普
伊尔凡·A·穆罕默德
库马雷什·索皮马思
尤里·V·艾利特切夫
张涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veluma Co ltd
Original Assignee
Nevada Ltd
Veluma Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64096170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110621298(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nevada Ltd, Veluma Co ltd filed Critical Nevada Ltd
Publication of CN110621298A publication Critical patent/CN110621298A/zh
Application granted granted Critical
Publication of CN110621298B publication Critical patent/CN110621298B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
CN201880031247.6A 2017-05-11 2018-05-10 阿托品药物组合物 Active CN110621298B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505027P 2017-05-11 2017-05-11
US62/505,027 2017-05-11
PCT/US2018/032017 WO2018209051A1 (en) 2017-05-11 2018-05-10 Atropine pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CN110621298A CN110621298A (zh) 2019-12-27
CN110621298B true CN110621298B (zh) 2022-12-20

Family

ID=64096170

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880031247.6A Active CN110621298B (zh) 2017-05-11 2018-05-10 阿托品药物组合物

Country Status (23)

Country Link
US (14) US10251875B2 (https=)
EP (2) EP3970694A1 (https=)
JP (5) JP6557379B2 (https=)
KR (1) KR102281667B1 (https=)
CN (1) CN110621298B (https=)
AU (1) AU2018265257B2 (https=)
CA (1) CA3063228C (https=)
CL (1) CL2019003228A1 (https=)
CO (1) CO2019012893A2 (https=)
CY (1) CY1124880T1 (https=)
ES (1) ES2901140T3 (https=)
HR (1) HRP20212019T1 (https=)
HU (1) HUE056595T2 (https=)
LT (1) LT3548000T (https=)
MX (1) MX392558B (https=)
PH (1) PH12019502701A1 (https=)
PL (1) PL3548000T3 (https=)
PT (1) PT3548000T (https=)
RS (1) RS62817B1 (https=)
RU (1) RU2745603C1 (https=)
SG (1) SG11201910085UA (https=)
SI (1) SI3548000T1 (https=)
WO (1) WO2018209051A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
CN117205209A (zh) * 2016-05-25 2023-12-12 新加坡保健服务集团 含有阿托品的水性组合物
US10251875B2 (en) 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions
JP7227163B2 (ja) 2017-06-10 2023-02-21 アイノビア，インコーポレイティド 流体を取扱い、目に流体を送出するための方法および装置
US11554115B2 (en) * 2018-03-14 2023-01-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative for treatment of triple-negative breast cancer
WO2019216395A1 (ja) * 2018-05-11 2019-11-14 千寿製薬株式会社 眼科用組成物
CN114533652B (zh) * 2018-09-25 2024-12-13 沈阳兴齐眼药股份有限公司 药物组合物、其制备方法和用途
WO2020219707A1 (en) * 2019-04-24 2020-10-29 Allergan, Inc. Compositions and methods for treatment of ocular conditions
WO2021001806A1 (en) * 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities
US12161585B2 (en) 2019-12-11 2024-12-10 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
IL293859A (en) * 2019-12-16 2022-08-01 Sydnexis Inc Ophthalmic preparations that include d2o
CN110917133A (zh) * 2019-12-23 2020-03-27 河北科技大学 一种治疗近视的滴眼剂及其制备方法
AU2021268189A1 (en) * 2020-05-05 2022-11-03 The Procter & Gamble Company Oral care compositions comprising dicarboxylic acid
CN111821259A (zh) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 一种眼用药物组合物
CN111840221A (zh) * 2020-08-25 2020-10-30 安徽博诺美科生物医药有限公司 一种硫酸阿托品滴眼液
WO2022130033A1 (en) * 2020-12-17 2022-06-23 Sun Pharmaceutical Industries Limited An aqueous sterile solution of atropine for ophthalmic use
PE20241644A1 (es) * 2021-03-16 2024-08-09 Vyluma Inc Envase multi-dosis para composiciones oftalmica
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
CN113440486B (zh) * 2021-06-02 2022-12-20 苏州欧康维视生物科技有限公司 一种用于预防或治疗眼科疾病的滴眼剂组合物及其制备方法
KR20240052048A (ko) * 2021-09-13 2024-04-22 오우푸시팡 파마수티칼 테크놀로지 씨오., 엘티디 아트로핀 점안액 및 이의 제조 방법
TW202333662A (zh) * 2021-11-10 2023-09-01 美商偉視醫療股份有限公司 增強抗老花眼效果之卡巴可(carbachol)調配物
CN114129511A (zh) * 2021-12-07 2022-03-04 河南润弘制药股份有限公司 一种具有改进稳定性的硫酸阿托品注射液
WO2023152642A1 (en) * 2022-02-08 2023-08-17 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
CN114569551A (zh) * 2022-03-21 2022-06-03 杭州赫尔斯科技有限公司 阿托品滴眼液及其制备方法
WO2023201315A2 (en) * 2022-04-14 2023-10-19 TearClear Corp. Ophthalmic agent in preservative removal device
CN115177584A (zh) * 2022-07-14 2022-10-14 成都市海通药业有限公司 一种硫酸阿托品注射液的制备方法
US20260083720A1 (en) * 2022-10-26 2026-03-26 Vyluma Inc. Childhood Atropine For Myopia Progression
CN115998692A (zh) * 2023-02-15 2023-04-25 苏州欧康维视生物科技有限公司 一种阿托品药物产品及其用途
WO2025146828A1 (ja) * 2024-01-05 2025-07-10 ロート製薬株式会社 眼科組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1144477A (zh) * 1994-03-31 1997-03-05 雷若斯公司 低粘度的眼药组合物
US20160009705A1 (en) * 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
CN106572998A (zh) * 2014-06-24 2017-04-19 西德奈克西斯公司 眼用组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86521A1 (fr) 1986-07-18 1988-02-02 Oreal Procede de teinture des cheveux avec des colorants hydroxyquinoniques et des sels metalliques
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US20030129083A1 (en) 1997-11-26 2003-07-10 Advanced Medical Optics, Inc. Multi purpose contact lens care compositions including propylene glycol or glycerin
US6164282A (en) 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
DK2153819T3 (da) * 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
CN101049287A (zh) 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
CN101820917B (zh) * 2007-10-08 2013-01-02 佛维雅制药股份有限公司 水性眼科配制剂
WO2010083129A2 (en) 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
US20120203161A1 (en) 2009-08-12 2012-08-09 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
ES2650748T3 (es) * 2013-01-31 2018-01-22 Senju Pharmaceutical Co. Ltd Solución acuosa estable
JP6208332B2 (ja) 2013-05-06 2017-10-04 カオシュン・チャン・グン・メモリアル・ホスピタル 医薬組成物及びその用途
EP3057575B1 (en) * 2013-10-15 2021-09-08 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
WO2016013993A1 (en) 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
KR20180014825A (ko) 2015-06-18 2018-02-09 프레스바이오피아 세라피스, 엘엘씨 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법
CN117205209A (zh) 2016-05-25 2023-12-12 新加坡保健服务集团 含有阿托品的水性组合物
US10251875B2 (en) * 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions
US11191751B1 (en) 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1144477A (zh) * 1994-03-31 1997-03-05 雷若斯公司 低粘度的眼药组合物
US20160009705A1 (en) * 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
CN106572998A (zh) * 2014-06-24 2017-04-19 西德奈克西斯公司 眼用组合物
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
硫酸阿托品滴眼剂稳定性的考察;钱海涛;《医药前沿》;20130331(第7期);123-124 *

Also Published As

Publication number Publication date
BR112019023515A2 (pt) 2020-05-19
US20200352928A1 (en) 2020-11-12
US20190175579A1 (en) 2019-06-13
US20240342154A1 (en) 2024-10-17
US11464769B2 (en) 2022-10-11
HUE056595T2 (hu) 2022-02-28
EP3548000B1 (en) 2021-11-10
AU2018265257A1 (en) 2019-11-14
JP2019172705A (ja) 2019-10-10
US20190209545A1 (en) 2019-07-11
US12036217B2 (en) 2024-07-16
JP6557379B2 (ja) 2019-08-07
US11071732B2 (en) 2021-07-27
LT3548000T (lt) 2022-03-10
US11642338B2 (en) 2023-05-09
US20200405705A1 (en) 2020-12-31
SG11201910085UA (en) 2019-11-28
JP6865476B2 (ja) 2021-04-28
HRP20212019T1 (hr) 2022-04-01
US20190192499A1 (en) 2019-06-27
CO2019012893A2 (es) 2020-02-28
US11730728B2 (en) 2023-08-22
RU2745603C1 (ru) 2021-03-29
US10576074B2 (en) 2020-03-03
US10610525B2 (en) 2020-04-07
EP3970694A1 (en) 2022-03-23
EP3548000A1 (en) 2019-10-09
MX2019013218A (es) 2022-05-24
KR102281667B9 (ko) 2024-01-08
US20190175580A1 (en) 2019-06-13
PL3548000T3 (pl) 2022-01-17
JP7332179B2 (ja) 2023-08-23
US20200397776A1 (en) 2020-12-24
US11707458B2 (en) 2023-07-25
NZ758555A (en) 2021-10-29
CN110621298A (zh) 2019-12-27
CY1124880T1 (el) 2022-11-25
JP2021102647A (ja) 2021-07-15
SI3548000T1 (sl) 2022-02-28
CA3063228C (en) 2022-06-28
US10251875B2 (en) 2019-04-09
EP3548000A4 (en) 2019-12-04
US20210128546A1 (en) 2021-05-06
CL2019003228A1 (es) 2020-01-31
JP2018188440A (ja) 2018-11-29
PH12019502701A1 (en) 2020-12-07
US20180325888A1 (en) 2018-11-15
US20190183876A1 (en) 2019-06-20
AU2018265257B2 (en) 2020-08-06
JP2019172704A (ja) 2019-10-10
KR102281667B1 (ko) 2021-07-23
PT3548000T (pt) 2021-12-10
JP6681503B2 (ja) 2020-04-15
JP2019194248A (ja) 2019-11-07
US10568875B2 (en) 2020-02-25
RS62817B1 (sr) 2022-02-28
KR20190138714A (ko) 2019-12-13
ES2901140T3 (es) 2022-03-21
JP6681502B2 (ja) 2020-04-15
WO2018209051A1 (en) 2018-11-15
MX392558B (es) 2025-03-24
US11730727B2 (en) 2023-08-22
US10583132B2 (en) 2020-03-10
US20230355604A1 (en) 2023-11-09
US20200397775A1 (en) 2020-12-24
USRE50040E1 (en) 2024-07-16
CA3063228A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
CN110621298B (zh) 阿托品药物组合物
HK40016019A (en) Atropine pharmaceutical compositions
HK40016019B (en) Atropine pharmaceutical compositions
HK40069136A (en) Atropine pharmaceutical compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016019

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20211026

Address after: New jersey, USA

Applicant after: Veluma Co.,Ltd.

Address before: New jersey, USA

Applicant before: Nevada Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant